Ngoi N - Search Results

1

PARP inhibitors: enhancing efficacy through rational combinations.

Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. Bhamidipati D, et al. Among authors: ngoi n. Br J Cancer. 2023 Oct;129(6):904-916. doi: 10.1038/s41416-023-02326-7. Epub 2023 Jul 10. Br J Cancer. 2023. PMID: 37430137 Free PMC article. Review.

2

The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers.

Wijaya ST, Ngoi NY, Tan DS. Wijaya ST, et al. Best Pract Res Clin Obstet Gynaecol. 2022 Jan;78:14-35. doi: 10.1016/j.bpobgyn.2021.06.003. Epub 2021 Aug 4. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 34456153 Review.

3

Outcomes of a Phase II Study of Intraperitoneal Paclitaxel plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases.

Chia DKA, Sundar R, Kim G, Ang JJ, Lum JHY, Nga ME, Goh GH, Seet JE, Chee CE, Tan HL, Ho J, Ngoi NYL, Lee MXW, Muthu V, Chan GHJ, Pang ASL, Ang YLE, Choo JRE, Lim JSJ, Teh JL, Lwin A, Soon Y, Shabbir A, So JBY, Yong WP. Chia DKA, et al. Ann Surg Oncol. 2022 Dec;29(13):8597-8605. doi: 10.1245/s10434-022-11998-z. Epub 2022 Sep 7. Ann Surg Oncol. 2022. PMID: 36070113 Clinical Trial.

4

Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises.

Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA. Pham MM, et al. Trends Cancer. 2021 Oct;7(10):958-970. doi: 10.1016/j.trecan.2021.05.004. Epub 2021 Jun 19. Trends Cancer. 2021. PMID: 34158277 Free PMC article. Review.

5

Targeting the replication stress response through synthetic lethal strategies in cancer medicine.

Ngoi NYL, Pham MM, Tan DSP, Yap TA. Ngoi NYL, et al. Trends Cancer. 2021 Oct;7(10):930-957. doi: 10.1016/j.trecan.2021.06.002. Epub 2021 Jun 30. Trends Cancer. 2021. PMID: 34215565 Free PMC article. Review.

6

A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.

Ngoi NYL, Peng G, Yap TA. Ngoi NYL, et al. Annu Rev Med. 2022 Jan 27;73:231-250. doi: 10.1146/annurev-med-042320-025136. Epub 2021 Oct 13. Annu Rev Med. 2022. PMID: 34644155 Review.

7

Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors.

Ngoi NYL, Leo E, O'Connor MJ, Yap TA. Ngoi NYL, et al. Cancer J. 2021 Nov-Dec 01;27(6):521-528. doi: 10.1097/PPO.0000000000000556. Cancer J. 2021. PMID: 34904816 Review.

8

Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.

Ngoi NYL, Westin SN, Yap TA. Ngoi NYL, et al. Curr Opin Oncol. 2022 Sep 1;34(5):559-569. doi: 10.1097/CCO.0000000000000867. Epub 2022 Jul 5. Curr Opin Oncol. 2022. PMID: 35787597 Free PMC article. Review.

9

A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer.

Sooi K, Walsh R, Kumarakulasinghe N, Wong A, Ngoi N. Sooi K, et al. Among authors: ngoi n. Cancer Drug Resist. 2023 Sep 25;6(3):656-673. doi: 10.20517/cdr.2023.48. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37842236 Free PMC article. Review.

10

Exploiting replicative stress in gynecological cancers as a therapeutic strategy.

Ngoi NY, Sundararajan V, Tan DS. Ngoi NY, et al. Int J Gynecol Cancer. 2020 Aug;30(8):1224-1238. doi: 10.1136/ijgc-2020-001277. Epub 2020 Jun 22. Int J Gynecol Cancer. 2020. PMID: 32571890 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters